ENGLEWOOD, Colo., June 14, 2019 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio"), today
announced that it intends to offer and sell shares of its common
stock in an underwritten public offering. Ampio expects to grant
the underwriters a 45-day option to purchase additional shares of
common stock offered in the public offering. The offering is
subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
Ampio intends to use the net proceeds from the proposed offering
for working capital and general corporate purposes, including
funding for its clinical trial (AP-013).
ThinkEquity, a division of Fordham Financial Management, Inc.,
is acting as sole book-running manager for the offering.
A shelf registration statement on Form S-3 (File No. 333-217094)
relating to the shares of common stock to be issued in the proposed
offering was filed with the Securities and Exchange Commission
(SEC) and is effective. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
A preliminary prospectus supplement and accompanying prospectus
describing the terms of the proposed offering will be filed with
the SEC. The securities may be offered only by means of a
prospectus, including a prospectus supplement, forming a part of
the effective registration statement. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
the securities being offered may also be obtained from ThinkEquity,
a division of Fordham Financial Management, Inc., 17 State Street,
22nd Floor, New York, New
York 10004, by telephone at (877) 436-3673, by email at
prospectus@think-equity.com. Electronic copies of the preliminary
prospectus supplement and accompanying prospectus will also be
available on the SEC's website at http://www.sec.gov.
Safe Harbor
This press release contains forward-looking statements
regarding the proposed public offering and the intended use of
proceeds from the offering. The offering is subject to market and
other conditions and there can be no assurance as to whether or
when the offering may be completed or as to the actual size or
terms of the offering. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that could cause
actual results to differ materially, including those risks
disclosed in under the caption "Risk Factors" in the preliminary
prospectus supplement related to the offering and our Annual Report
on Form 10-K filed with the SEC on March 18,
2019, our Quarterly Report on Form 10-Q filed with the SEC
on May 10, 2019 and our other filings
with the SEC. Ampio Pharmaceutcials, Inc. cautions readers not to
place undue reliance on any forward-looking statements and it does
not undertake, and specifically disclaims any obligation, to update
or revise such statements to reflect new circumstances or
unanticipated events as they occur.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-300868000.html
SOURCE Ampio Pharmaceuticals, Inc.